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ABSTRACT 
 
Background: Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed 
worldwide since 2008 for the primary and secondary prevention and treatment of 
thromboembolic disorders. Although liver injury was observed in premarketing trials of 
rivaroxaban, there are no published postmarketing cases of liver injury associated with 
rivaroxaban. 
Methods: Report of 14 cases of liver injury associated with rivaroxaban, including two with 
liver biopsy, and search queries in three large international pharmacovigilance databases for 
comparable cases. 
Results: Formal causality assessment classified rivaroxaban as the “highly probable”, 
“probable” and “possible” cause in 4, 7 and 3 patients, respectively. Search results from 
three large international pharmacovigilance databases revealed a considerable number of 
additional hepatic adverse events where rivaroxaban was reported as a suspected cause. 
Conclusions: We interpret the presented information as a relevant safety signal that should 
be followed by pharmacoepidemiological studies in order to reliably estimate absolute and 
relative risks of liver injury associated with rivaroxaban in support of rational risk-benefit 
assessment. Meanwhile, incident symptoms and signs of liver disease in patients treated 
with rivaroxaban should be considered as a potential adverse drug reaction, and if no other 
likely cause can be identified rivaroxaban should be stopped as soon as possible. 
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INTRODUCTION 
Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 
2008 for the primary and secondary prevention and treatment of thromboembolic disorders 
[1, 2]. Although liver injury was observed in premarketing trials of rivaroxaban [3], 
postmarketing cases of liver injury associated with rivaroxaban have not been published so 
far. Safety issues of newly marketed drugs including drug-induced liver injury (DILI) are 
typically identified during the first five years after marketing, and spontaneous reporting 
systems play an important role as a sensitive source of information for the detection of new 
postmarketing safety signals. We therefore evaluated postmarketing cases of liver injury 
associated with rivaroxaban reported to our regional pharmacovigilance center and 
performed search queries in three large international pharmacovigilance databases for 
comparable cases. 
 
 
CASE PRESENTATIONS 
 
Case #1 
A 78-year-old male patient had total knee replacement for which he received 
thromboprophylaxis with dalteparin for 10 days and thereafter rivaroxaban (Xarelto®, Bayer 
HealthCare) 10 mg/d. Approximately 14 days after start of rivaroxaban the patient developed 
painless jaundice, pruritus, fatigue, nausea and unintentional weight loss of 5 kg. 
Rivaroxaban was stopped 19 days after start, but it was not until another 10 days later that 
the patient was rehospitalized with determination of laboratory values. Upon admission 
alanine aminotransferase (ALT), alkaline phosphatase (AP) and total bilirubin (TB) were 
increased 2.5, 2.9 and 15.5 times the upper limit of normal (ULN), respectively. Viral serology 
and autoantibodies were negative. Abdominal ultrasound and computer tomography (CT) 
showed cholecystolithiasis but no signs of biliary obstruction. A liver biopsy was performed 
20 days after discontinuation of rivaroxaban. Histology showed cholestasis and portal 
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inflammation with eosinophilic infiltrates, compatible with drug-induced liver injury (Figure). 
Other recently administered drugs were a single i.v. dose of 2g cefazolin before knee 
replacement and postoperative analgesic treatment with acetaminophen and metamizole 
(=dipyrone) up to 4 g/day each for 10 days. During the further course the patient eventually 
developed a paralytic ileus and died 6 weeks after rehospitalization. The findings are also 
summarized in Table 1. 
According to standardized RUCAM criteria for the assessment of drug-induced liver injuries 
[4-6] we assigned a causality of “highly probable” (total score: 9) to rivaroxaban. Key criteria 
for this assessment were a close and plausible temporal relationship, a known and labeled 
adverse drug reaction, compatible histological findings, and negative differential diagnosis for 
alternative causes. Specifically, temporal relationship, only mild ALT increase and histology 
were not compatible with acetaminophen hepatotoxicity; dalteparin and metamizole had 
been stopped approximately 14 days, and cefazolin single dose was given 24 days before 
onset of symptoms. Other drugs were therefore classified as unlikely alternative causes. 
 
Case #2 
An 83-year-old female patient had total knee replacement for which she received 
thromboprophylaxis with dalteparin for 9 days and thereafter rivaroxaban 10 mg/d. 
Approximately 13 days after start of rivaroxaban the patient developed painless jaundice, 
pruritus, fatigue, nausea and unintentional weight loss of 5 kg. Twenty days after start of 
rivaroxaban the patient was rehospitalized, and another day later rivaroxaban was replaced 
by dalteparin. Upon admission ALT, AP and TB were increased 7.8, 6.8 and 13.9 times the 
ULN, respectively (Table 1). Viral serology and autoantibodies were negative. Abdominal 
ultrasound and CT showed cholecystolithiasis but no signs of biliary obstruction. A liver 
biopsy was performed 5 days after stop of rivaroxaban and was compatible with drug-
induced liver injury showing a similar histology (Figure) as in case #1. Other recently 
administered drugs were a single i.v. dose of 2g cefazolin before knee replacement and 
analgesic treatment with acetaminophen 4 g/day and diclofenac 150 mg/d for 9 days 
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postoperatively (followed by an on-demand prescription for another 20 days, but unknown 
actual use), and metamizole 1000 mg and 500 mg on postoperative days 1 and 3, 
respectively. The patient was treated with cholestyramine and subsequently recovered over 
the following weeks. 
Formal RUCAM assessment classified rivaroxaban‘s causality as “possible” (total score: 5), 
based on the key criteria of a close and plausible temporal relationship, a known and labeled 
adverse drug reaction, compatible histological findings and negative differential diagnosis for 
alternative causes except for diclofenac use. Nevertheless, in contrast to rivaroxaban, fixed-
dose diclofenac was stopped 16 days before onset of symptoms, and rivaroxaban therefore 
remains the most likely cause of liver injury. 
 
Cases #3-14 
Over the past 4 years and in our function as a regional pharmacovigilance center we 
received another 12 reports of liver injury associated with rivaroxaban and an at least 
possible causal relationship based on RUCAM criteria. In addition to our primary 
documentation we now performed an extensive reevaluation including formal causality 
assessment. For that purpose we contacted primary reporters and other treating physicians 
and hospitals and obtained all available relevant follow-up information. These cases are 
summarized in Table 1, and their detailed RUCAM classifications are presented in Table 2. 
 
REPORTS IN INTERNATIONAL PHARMACOVIGILANCE DATABASES 
Cases of liver injury associated with rivaroxaban should be reported to pharmacovigilance 
systems worldwide, and we therefore also performed searches in databases of international 
postmarketing spontaneous reporting systems. The database of the World Health 
Organization (WHO UMC VigiBase, access date 2013-11-28) contains, including our own 
cases, reports of 179 cases that are compatible with DILI (classified under 19 selected 
hepatobiliary WHO-ART reaction terms) where rivaroxaban was reported as a suspected 
cause; the database of the European Medicines Agency (EMA EudraVigilance, access date 
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2013-11-03, data censored 30 September 2013) contains 375 events classified under 21 
selected hepatobiliary MedDRA reaction terms where rivaroxaban was a suspected cause; 
and the database of the US Food and Drug Administration (FDA FAERS, data censored 31 
December 2012, extracted in November 2013 by the FDA in response to our request under 
the Freedom of Information Act) contains 87 cases classified under the 21 selected MedDRA 
terms. For details on searched terms and reported hepatic events see supplementary 
material (S.1). 
These reports have limitations and must therefore be interpreted with caution: in the absence 
of detailed information the causal role of rivaroxaban regarding the reported hepatic 
outcomes remains uncertain; due to unknown reporting rates and population exposure 
spontaneous reporting systems cannot provide reliable quantitative risk estimates; 
pharmacovigilance systems may contain duplicate reports, and in our EudraVigilance search 
several adverse events may refer to only one individual case. Nevertheless, these reports 
can be interpreted as a signal in support of the hypothesis that our cases may represent just 
the “tip of the iceberg” of a considerably larger number of serious liver injuries worldwide 
caused by rivaroxaban. 
 
DISCUSSION 
Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 
2008 for the primary and secondary prevention and treatment of thromboembolic disorders. 
Five years after market launch we are not aware of any published detailed postmarketing 
case reports of liver injury associated with rivaroxaban. However, liver injury is known under 
rivaroxaban, labeled adverse reactions include icterus and increased transaminases, alkaline 
phosphatase, and total and conjugated bilirubin [7]. Of note, the direct thrombin inhibitor 
ximelagatran was associated with hepatotoxicity during clinical development, which 
contributed to non-approval by the US FDA, and in other countries marketing was 
discontinued after serious cases of liver injury associated with ximelagatran appeared in the 
postmarketing phase [8]. Looking at premarketing data of rivaroxaban, a published 
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evaluation of rivaroxaban’s hepatic events in clinical trials was based on its phase III 
RECORD studies and included 6131 patients exposed to rivaroxaban. The featured analysis 
used state of the art eDISH plots [3] and identified ALT increases ≥3x ULN in 2.3% of 
patients including 9 apparent “Hy’s cases” with a simultaneous ≥2x increase in total bilirubin. 
Further validations concluded that there was only one “true” Hy’s case either caused by 
rivaroxaban or possibly by other incompletely excluded alternate etiologies [3]. A recent 
systematic review and meta-analysis of premarketing data on liver injury associated with new 
oral anticoagulants reported ambiguous results. There were a large number of cases with 
ALT elevations >3x ULN including many with concomitant total bilirubin >2x ULN subsequent 
to the use of those drugs. At the same time there were no evident risk differences between 
the individual studied new oral anticoagulants, and a lower risk of such events when 
compared to low molecular weight heparins [9]. However, safety analyses of clinical trials’ 
data have intrinsic limitations. According to the “Rule of 3” [10, 11] the 6131 exposed patients 
in the RECORD studies are insufficient to reliably detect risks of less than approximately 
1:2000, which is typical for idiosyncratic drug-induced liver disease (DILI) but can still be 
relevant for a drug’s overall risk-benefit evaluation [12]. Another limitation is that the duration 
of treatment in these trials was only 35±2 or 12±2 days, respectively [3]. This is shorter than 
the currently labeled treatment time for some indications, and 12±2 days are also less than 
the median latency time of 15.5 days in our case series. Risk factors are another issue of 
particular interest, as they are often underrepresented in clinical trial populations. 
Rivaroxaban is often started after orthopedic surgery and many patients concomitantly 
receive potentially hepatotoxic analgesic drugs. Our series included three patients meeting 
biochemical criteria of Hy’s cases but concomitant use of acetaminophen in therapeutic 
doses. Dose, long latency time and histology were not compatible with acetaminophen-
induced hepatotoxicity in these cases. However, according to current mechanistic concepts 
acetaminophen in doses below the hepatotoxic threshold may attenuate hepatotoxic 
“downstream” pathways via glutathione depletion and cytokine-mediated signal transduction. 
Acetaminophen could therefore have acted as a risk factor for rivaroxaban-induced liver 
  
 
8
injury [13, 14]. Some patients also received metamizole, but hepatotoxicity is not amongst its 
labeled adverse reactions. Indeed, we found only one case of metamizole-associated liver 
injury in the literature [15], but it presented with an allergic skin reaction after short latency, 
which is different from the pattern observed in our cases. In order to further clarify the 
causality in our case series, we planned the conduct of lymphocyte transformation tests 
(LTT) with in-vitro exposure of lymphocytes from our patients to rivaroxaban. This method 
has been successfully used for the evaluation of DILI in the past [16]. These planned studies 
have been delayed because we were unable to obtain rivaroxaban pure substance from the 
manufacturer of Xarelto®, but we now aim to perform these tests with commercially available 
rivaroxaban. 
 
Possible mechanisms of rivaroxaban-induced hepatotoxicity are unknown and probably 
involve complex interactions of several rare factors, possibly also immune-mediated 
reactions. Of further note, previous studies indicated that rivaroxaban is a shared substrate 
of the drug transport proteins MDR1 and BCRP, whereas anticoagulant vitamin K 
antagonists are no strong substrates of MDR1 [17-19]. MDR1 inhibitors and loss-of-function 
BCRP polymorphisms may therefore alter rivaroxaban pharmacokinetics, and further studies 
may explore the potential role of these factors for rivaroxaban-induced DILI.  
 
The diagnosis of drug-induced liver injury mainly depends on temporal relationship and the 
exclusion of other causes, which can never be done with absolute certainty. Furthermore, 
even the widely accepted RUCAM causality scale for DILI has limitations, and discrepancies 
between expert evaluations vs. standardized scales have been widely discussed and studied 
[6, 20, 21]. At least all cases reported to our center were evaluated using senior expertise 
and the most recognized standardized DILI-specific criteria. In contrast, the routine 
evaluation of cases that are reported to large pharmacovigilance databases usually lacks 
detailed case information and sufficient resources for standardized DILI-specific causality 
assessments. In order to avoid over-interpretation it is therefore reasonable that publicly 
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available search results from those databases only contain the information whether a specific 
drug is considered as an at least possible cause. Furthermore, we also recognize that some 
individual cases may have been reported to more than one of the searched databases. 
Spontaneous reports are neither meant to provide definite proof for the causative role of 
rivaroxaban in the presented cases, nor can they be used for reliable calculations of 
quantitative risk estimates. However, we applied the best possible combination of 
standardized causality assessment plus expert evaluation, and in our long-term experience 
as a pharmacovigilance center the presented case series of liver injury in association with a 
newly marketed drug is unusual and reason to raise concern. Premarketing experience and 
information from international pharmacovigilance databases are also compatible with the 
possibility that rivaroxaban continues to cause a considerable absolute number of liver 
injuries worldwide. In conclusion, we therefore interpret the presented case series as a 
potentially serious signal that requires follow-up by pharmacoepidemiological cohort studies 
in suitable databases in order to estimate the absolute and relative risks of serious liver injury 
associated with rivaroxaban versus alternative anticoagulants [12]. Meanwhile, the 
apparently rare but potentially serious risk of rivaroxaban-induced liver injury should be 
considered in the risk-benefit evaluation versus alternative antithrombotic drugs with 
established safety profiles. In patients treated with rivaroxaban incident symptoms and signs 
of liver disease should be considered as a potential adverse drug reaction, and if no other 
likely cause can be identified rivaroxaban should be stopped as soon as possible.
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FIGURE  
see separate file (figure_rivaroxaban_russmann.pdf) 
 
 
LEGEND FOR FIGURE 
 
Liver histology in cases #1 and #2 
Histology in the two patients where needle liver biopsies were performed revealed almost identical 
morphological findings with more pronounced changes in case #2. Liver parenchyma shows a 
centrilobular accentuated cholestasis (1A arrow) with prominent Kupffer cells and focal ballooning of 
periportal hepatocytes (1B). There is a mainly portal inflammation of mixed cellularity, focal with many 
eosinophilic granulocytes and some periductal reinforcement (2A, 1B). Interlobular bile ducts show an 
alteration of the epithelium with intraepithelial lymphocytes (2B and inset, arrow) and some ductular 
reaction (2, inset, arrowhead). No ductopenia or fibrosis is present. 
(hematoxylin and eosin stain; inset figure 2: cytokeratin 7 immunohistochemistry stain of bile ducts) 
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Table 1 - Case presentations 
 
see separate file (Table1_rivaroxaban_russmann.pdf) 
 
 
Table 2 
Detailed RUCAM causality assessments and scores for all 14 reported cases 
 
see separate file (Table2_rivaroxaban_russmann.pdf) 
 
 
  
  
TABLE	  1
Case	  # Age Sex Rivaroxaban	  
indication
Rivaroxaban	  
dose/day
Rivaroxaban	  
treatment	  
duration
Latency	  
time1
Symptoms ALT	  (xULN)2	  
initial	  	  	  	  	  	  	  	  	  	  	  
max
AP	  (xULN)3	  
initial	  	  	  	  	  	  	  
max
R4 TB	  (xULN)5	  
initial	  	  	  	  	  	  	  	  	  	  
max
Outcome Differential	  diagnosis RUCAM6	  
causality	  score
RUCAM6	  
causality	  class
Comments
1 78 m Knee	  
replacement
20	  mg 19	  days 14	  days Painless	  jaundice,	  
nausea
2.5	  (day30) 2.9	  (day	  30) 0.8 15.5	  (day	  30)	  	  
21.6	  (day	  42)
Death	  
(paralytic	  
ileus)
Vira	  serology	  for	  HBV,	  HCV,	  CMV,	  EBV	  negative;	  
autoantibodies	  and	  imaging	  negative.	  No	  other	  
suspicious	  drugs	  or	  events	  causing	  liver	  injury	  
identified.
9 Highly	  
probable
Liver	  biopsy	  performed	  (see	  Figure)
2 83 f Knee	  
replacement
10	  mg 21	  days 16	  days Painless	  jaundice,	  
nausea
7.8	  (day20) 6.8	  (day20)	  
7.1	  (day	  29)
1.2 13.9	  (day	  20)	  	  
17.1	  (day	  27)
Recovery Viral	  serology	  for	  HAV,	  HBV,	  HCV,	  CMV,	  EBV	  
negative;	  autoantibodies	  and	  imaging	  negative.	  
Diclofenac	  alternative	  possible	  cause.
5 Possible Liver	  biopsy	  performed	  (see	  Figure)
3 74 m Atrial	  fibrillation 20	  mg 51	  days <50	  days Painless	  jaundice 4	  (day	  51)	  	  	  	  
5.1	  (day	  55)
<1	  (day	  51) 5.1 3.1	  (day	  51)	  	  
3.7	  (day	  52)
Recovery Viral	  serology	  for	  HBV	  negative;	  IgG	  and	  imaging	  
negative.	  No	  other	  suspicious	  drugs	  or	  events	  
causing	  liver	  injury	  identified.
7 Probable Meets	  biochemical	  criteria	  for	  Hy's	  case7.
4 63 m Atrial	  fibrillation 20	  mg 6	  days 5	  days Nausea	  and	  
vomiting
7.8	  (day	  7) <1	  (day	  6) 7.8 <1	  (day	  6) Recovery Amiodarone	  600	  mg/d	  may	  be	  alternative	  or	  
contributory	  cause.	  No	  other	  events	  that	  suggest	  
alternative	  cause.	  
3 Possible Nausea	  improved	  immediately	  after	  stop	  of	  
rivaroxaban	  while	  high	  dose	  amiodarone	  was	  
continued	  (no	  follow-­‐up	  of	  ALT	  available).
5 91 f Atrial	  fibrillation 15	  mg 34	  days 14	  days Painless	  jaundice,	  
nausea
2.5	  (day	  34) 7.8	  (day	  37) 0.3 8.4	  (day	  34) Recovery Viral	  serology	  for	  HAV,	  HBV,	  HCV,	  HDV,	  HEV	  
negative;	  ANA,	  ANCA,	  Anti-­‐MPO,	  Anti-­‐PR3	  negative;	  
imaging	  negative.	  No	  other	  suspicious	  drugs	  or	  
events	  causing	  liver	  injury	  identified.
9 Highly	  
probable
6 64 f Atrial	  fibrillation 20mg 40	  days <40	  days No	  symptoms 6.3	  (day	  40) 1.5	  (day	  40) 4.1 n.a. Recovery No	  other	  suspicious	  drugs	  or	  events	  causing	  liver	  
injury	  identified.
7 Probable
7 75 m Knee	  
replacement
20mg 15	  days 15	  days Painless	  jaundice 10.6	  (day	  18)	  	  
11.3	  (day	  22)
3.2	  (day	  18)	  	  	  
6.2	  (day	  33)
3.4 4.5	  (day	  18)	  	  	  
9.0	  (day	  22)
Recovery Imaging	  negative;	  HBV,	  HCV,	  EBV,	  CMV,	  ANA,	  Anti-­‐
dsDNA	  and	  IgG	  negative.	  No	  other	  suspicious	  drugs	  
or	  events	  causing	  liver	  injury	  identified.
9 Highly	  
probable
8 69 f Knee	  arthroscopy 10mg 10	  days 13	  days Fatigue,	  loss	  of	  
appetite
2.7	  (day	  12) <1	  (day	  26) 2.7 n.a. Recovery No	  differential	  diagnostic	  investigations	  performed,	  
because	  presentation	  and	  history	  did	  not	  suggest	  
alternative	  causes.	  No	  other	  suspicious	  drugs	  or	  
events	  causing	  liver	  injury	  identified.
9 Highly	  
probable
"Positive	  rechallenge":	  Reexposure	  to	  rivaroxaban	  
after	  knee	  replacement	  6	  months	  later	  with	  
subsequent	  increase	  of	  AP	  (2.8	  xULN)	  11	  days	  after	  
surgery	  and	  restart	  of	  rivaroxaban;	  again	  recovery	  
after	  stop.
9 61 f Knee	  surgery	  
(cruciate	  
ligament	  plasty)
10mg 24	  days 20	  days Jaundice,	  nausea,	  
pruritus
13.6	  (day	  24) 1.5	  (day	  24) 9.3 3.7	  (day	  24) Recovery HBV	  vaccinated.	  Acetaminophen	  possibly	  
contributory	  but	  unlikely	  primary	  cause	  (only	  
3g/day,	  jaundice	  and	  long	  latency	  time	  not	  typical	  
for	  intrinsic	  acetaminophen	  hepatotoxicity).
6 Probable Meets	  biochemical	  criteria	  for	  Hy's	  case7.	  
Acetaminophen	  may	  have	  contributed	  to	  ALT	  
increase.
10 60 f Knee	  
replacement
10mg 17	  days 14	  days Jaundice,	  fatigue,	  
vomiting,	  
18.6	  (day	  17)	  
19.9	  (day	  20)
n.a. n.a. 4.2	  (day	  17)	  
8.4	  (day	  13)
Recovery Imaging	  negative;	  HAV,	  HBV,	  HCV,	  ANA,	  Anti-­‐
SLA/SM/mitochondria	  negative.	  No	  other	  suspicious	  
drugs	  or	  events	  causing	  liver	  injury	  identified.
6 Probable Meets	  biochemical	  criteria	  for	  Hy's	  case7.	  
Acetaminophen	  may	  have	  contributed	  to	  ALT	  
increase.
11 41 f Leg	  surgery	  after	  
trimalleolar	  Fx
10mg 27	  days 20	  days Jaundice,	  nausea	  
and	  vomiting,	  
pruritus
	  53.7	  (day	  27) 3.4	  (day	  27) 15.6 4.8	  (day	  30)	  	  	  	  	  -­‐Recovery HAV,	  HBV,	  HCV,	  HEV,	  CMV,	  EBV,	  ANA	  and	  Anti-­‐sm	  
negative,	  IgG	  normal.	  Imaging	  negative.	  No	  other	  
suspicious	  drugs	  or	  events	  causing	  liver	  injury	  
identified.
7 Probable Meets	  biochemical	  criteria	  for	  Hy's	  case7.	  
Acetaminophen	  may	  have	  contributed	  to	  ALT	  
increase.
12 78 f Knee	  
replacement
10mg 62	  days 62	  days Jaundice,	  nausea,	  
diarrhea
14	  (day	  62) 2.1	  (day	  62) 6.5 n.a. Recovery Acetaminophen	  postoperatively	  not	  documented	  
but	  possible.	  No	  suggestion	  for	  alternative	  causes	  
but	  no	  formal	  exclusion.
5 Possible
13 73 m Knee	  
replacement
10mg 3	  days 3	  days Jaundice,	  nausea,	  
mild	  pain
6.1	  (day	  5) 2.5	  (day	  5) 2.5 n.a. Recovery Imaging	  negative.	  No	  other	  suspicious	  drugs	  or	  
events	  causing	  liver	  injury	  identified.
6 Probable Unusually	  short	  latency	  time.	  Cefazolin	  preoperative	  
single	  i.v.	  application,	  but	  cefazolin	  previously	  well	  
tolerated.
14 42 f Leg	  surgery	  after	  
Maisonneuve-­‐Fx
10mg 31	  days 29	  days Jaundice,	  nausea 23.5	  (day	  30) 3.2	  (day	  30) 7.3 2.8	  (day	  30)	  	  	  	  
3.0	  (day	  54)
Recovery Viral	  serology	  and	  autoantibodies	  negative.	  No	  
other	  suspicious	  drugs	  or	  events	  causing	  liver	  injury	  
identified.
8 Probable
Legend	  Table	  1
1 Time	  from	  start	  of	  rivaroxaban	  to	  first	  symptoms	  or	  signs	  of	  liver	  injury.
2 Alanine	  aminotransferase,	  expressed	  as	  multiples	  of	  upper	  limit	  of	  normal.	  Time	  in	  relation	  to	  start	  of	  rivaroxaban.
3 Alkaline	  phosphatase,	  expressed	  as	  multiples	  of	  upper	  limit	  of	  normal.	  Time	  in	  relation	  to	  start	  of	  rivaroxaban.
4 Laboratory	  classification	  of	  drug-­‐induced	  liver	  injury	  (see	  also	  reference	  2),	  where	  R	  =	  ratio	  ALT/AP,	  where	  both	  are	  expressed	  as	  multiples	  of	  upper	  limit	  of	  normal
5 Total	  bilirubin,	  expressed	  as	  multiples	  of	  upper	  limit	  of	  normal.	  Time	  in	  relation	  to	  start	  of	  rivaroxaban.
6 Roussel	  Uclaf	  Causality	  Assessment	  Method,	  endorsed	  by	  the	  Council	  of	  International	  Organizations	  of	  Medical	  Sciences	  (see	  also	  references	  1	  and	  2).
7 Hy's	  case	  criteria:	  ALT	  >3x	  ULN	  and	  TB	  >2x	  ULN	  without	  initial	  AP	  increase	  /	  cholestatic	  enzyme	  pattern	  (see	  also	  reference	  6).
  
Supplemental	  material	  S1	  -­‐	  Detailed	  RUCAM	  causality	  assessments	  and	  scores	  for	  all	  14	  reported	  cases
Case	  # 1 2 3 4 5 6 7 8 9 10 11 12 13 14
RUCAM	  criteria
hepatocell	  or	  chol/mix	   chol chol hepatocell hepatocell chol mix mix ? hepatocell ? hepatocell hepatocell mix hepatocell
1	  (temporal	  relationship) 2 2 2 2 2 2 2 1 2 2 2 2 1 2
2	  (course	  after	  drug	  cessation) 2 0 2 0 2 2 1 2 3 2 3 2 2 2
3.1	  (risk	  factors,	  alcohol) 0 0 0 0 0 0 1 0 0 0 0 0 0 0
3.2	  (risk	  factors,	  age) 1 1 1 1 1 1 1 1 1 1 0 1 1 0
4	  (concomitant	  drugs) 0 -­‐2 0 -­‐2 0 0 0 -­‐2 -­‐2 -­‐2 -­‐2 -­‐2 0 0
5	  (exclusion	  of	  non-­‐drug	  causes) 2 2 0 0 2 0 2 2 0 1 2 0 0 2
6	  (labeling	  /	  previous	  information	  on	  hepatotoxicity) 2 2 2 2 2 2 2 2 2 2 2 2 2 2
7	  (rechallenge) 0 0 0 0 0 0 0 3 0 0 0 0 0 0
TOTAL	  SCORE 9 5 7 3 9 7 9 9 6 6 7 5 6 8
Score	  interpretation highly	  prob possible probable possible highly	  prob probable highly	  prob highly	  prob probable probable probable possible probable probable
For	  detailed	  description	  of	  RUCAM	  criteria	  see	  also	  references	  1	  (Aithal	  et	  al.	  2011)	  and	  2	  (Danan	  and	  Benichou	  1993)
score
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SUPPLEMENTAL MATERIAL (may be used for online only publication) 
 
 
S1 
Detailed search criteria and results for hepatobiliary disorders compatible with drug-induced 
liver injury in international pharmacovigilance databases 
 
see separate file (S1_rivaroxaban_russmann.pdf) 
 
  
Supplemental	  material	  S2	  -­‐	  Detailed	  search	  criteria	  and	  results	  for	  hepatobiliary	  disorders	  compatible	  with	  drug-­‐induced	  liver	  injury	  in	  international	  pharmacovigilance	  databases
WHO	  UMC	  VigiBase	   EMA EudraVigilance US FDA FAERS
Access	  date	  2013-­‐11-­‐28 Access	  date	  2013-­‐11-­‐03,	  data	  censored	  30	  September	  2013 Extracted	  in	  November	  2013,	  data	  censored	  31	  December	  2012	  
WHO-­‐ART	  reaction	  term n	  total	  events MedDRA	  Preferred	  Term n	  total	  events MedDRA	  Preferred	  Term n	  total	  events
Cholestasis 10 acute	  hepatic	  failure 12 acute	  hepatic	  failure 2
Hepatitis	  cholestatic 9 cholestasis 20 cholestasis 11
Jaundice 45 cholestatic	  liver	  injury 6 cholestatic	  liver	  injury 2
Liver	  disorder	   11 drug	  induced	  liver	  injury 19 drug	  induced	  liver	  injury 7
Liver	  injury 7 hepatic	  failure 24 hepatic	  failure 11
Acute	  hepatic	  failure 5 hepatic	  function	  abnormal 30 hepatic	  function	  abnormal 3
Hepatic	  failure 17 hepatitis 29 hepatitis 16
Drug-­‐induced	  liver	  injury 10 hepatitis	  acute 5 hepatitis	  acute 2
Hepatitis 9 hepatitis	  cholestatic 9 hepatitis	  cholestatic 3
Hepatitis	  acute 4 hepatitis	  toxic 7 hepatitis	  toxic 1
Hepatitis	  toxic 5 hepatocellular	  injury 37 hepatocellular	  injury 2
Hepatotoxicity 5 hepatotoxicity 8 hepatotoxicity 1
Alanine	  aminotransferase	  increased 48 jaundice 65 jaundice 20
Jaundice	  cholestatic 1 jaundice	  cholestatic 1 jaundice	  cholestatic 1
Hepatocellular	  injury 9 jaundice	  hepatocellular 1 jaundice	  hepatocellular 0
Subacute	  hepatic	  failure 1 liver	  disorder 25 liver	  disorder 10
Blood	  bilirubin	  increased 23 liver	  injury 4 liver	  injury 8
Jaundice	  hepatocellular 1 mixed	  liver	  injury 3 mixed	  liver	  injury 2
Mixed	  liver	  injury 2 subacute	  hepatic	  failure 1 subacute	  hepatic	  failure 1
Total	  WHO-­‐ART	  reaction	  terms	  (events) 222 alanine	  aminotransferase	  increased 43 alanine	  aminotransferase	  increased 17
blood	  bilirubin	  increased 26 blood	  bilirubin	  increased 10
n	  total	  individual	  cases Total	  Preferred	  Terms	  (events) 375 Total	  Preferred	  Terms	  (events) 130
after	  exclusion	  of	  several	  events	  /	  case 179
n	  total	  individual	  cases
no	  preferred	  term	  level	  access	  for	  exclusion	  of	  several	  events/case after	  exclusion	  of	  several	  events	  /	  case 87
(n	  individual	  cases	  for	  all	  hepatobiliary	  disorders	  =	  298)
